Reducing Onboard Processing Time for Path Planning in Dynamically Evolving Polygonal Maps

Autonomous agents face the challenge of coordinating multiple tasks (perception, motion planning, controller) which are computationally expensive on a single onboard computer. To utilize the onboard processing capacity optimally, it is imperative to arrive at computationally efficient algorithms for global path planning. In this work, it is attempted to reduce the processing time for global path planning in dynamically evolving polygonal maps. In dynamic environments, maps may not remain valid for long. Hence it is of utmost importance to obtain the shortest path quickly in an ever-changing environment. To address this, an existing rapid path-finding algorithm, the Minimal Construct was used. This algorithm discovers only a necessary portion of the Visibility Graph around obstacles and computes collision tests only for lines that seem heuristically promising. Simulations show that this algorithm finds shortest paths faster than traditional grid-based A* searches in most cases, resulting in smoother and shorter paths even in dynamic environments.

Machine-Learning Driven Drug Repurposing for COVID-19

The integration of machine learning methods into bioinformatics provides particular benefits in identifying how therapeutics effective in one context might have utility in an unknown clinical context or against a novel pathology. We aim to discover the underlying associations between viral proteins and antiviral therapeutics that are effective against them by employing neural network models. Using the National Center for Biotechnology Information virus protein database and the DrugVirus database, which provides a comprehensive report of broad-spectrum antiviral agents (BSAAs) and viruses they inhibit, we trained ANN models with virus protein sequences as inputs and antiviral agents deemed safe-in-humans as outputs. Model training excluded SARS-CoV-2 proteins and included only Phases II, III, IV and Approved level drugs. Using sequences for SARS-CoV-2 (the coronavirus that causes COVID-19) as inputs to the trained models produces outputs of tentative safe-in-human antiviral candidates for treating COVID-19. Our results suggest multiple drug candidates, some of which complement recent findings from noteworthy clinical studies. Our in-silico approach to drug repurposing has promise in identifying new drug candidates and treatments for other viruses.

SynGAN: Towards Generating Synthetic Network Attacks using GANs

The rapid digital transformation without security considerations has resulted in the rise of global-scale cyberattacks. The first line of defense against these attacks are Network Intrusion Detection Systems (NIDS). Once deployed, however, these systems work as blackboxes with a high rate of false positives with no measurable effectiveness. There is a need to continuously test and improve these systems by emulating real-world network attack mutations. We present SynGAN, a framework that generates adversarial network attacks using the Generative Adversial Networks (GAN). SynGAN generates malicious packet flow mutations using real attack traffic, which can improve NIDS attack detection rates. As a first step, we compare two public datasets, NSL-KDD and CICIDS2017, for generating synthetic Distributed Denial of Service (DDoS) network attacks. We evaluate the attack quality (real vs. synthetic) using a gradient boosting classifier.